|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.630 USD | +1.24% |
|
-1.21% | +32.50% |
Company Valuation: Interpace Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 12.69 | 31.18 | 4.437 | 4.693 | 11.87 | 5.448 |
| Change | - | 145.72% | -85.77% | 5.76% | 152.98% | -54.11% |
| Enterprise Value (EV) 1 | 14.8 | 41.84 | 15.7 | 12.39 | 16.27 | 4.126 |
| Change | - | 182.66% | -62.47% | -21.1% | 31.32% | -74.64% |
| P/E | -0.43x | -2.06x | -0.2x | 6.03x | 6.84x | 1.39x |
| PBR | -0.44x | -0.74x | -0.07x | -0.08x | -5.36x | 0.25x |
| PEG | - | 0x | -0x | -0x | 0x | 0x |
| Capitalization / Revenue | 0.39x | 0.75x | 0.14x | 0.12x | 0.25x | 0.14x |
| EV / Revenue | 0.46x | 1.01x | 0.49x | 0.31x | 0.35x | 0.11x |
| EV / EBITDA | -0.7x | -6.28x | -12.3x | 3.23x | 1.93x | 0.79x |
| EV / EBIT | -0.56x | -3.56x | -4.09x | 4.41x | 2.01x | 0.86x |
| EV / FCF | -2.21x | -25.8x | -15.1x | 2.93x | 11.5x | 0.81x |
| FCF Yield | -45.2% | -3.87% | -6.64% | 34.1% | 8.66% | 123% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -7.322 | -3.618 | -5.181 | 0.179 | 0.3945 | 0.8852 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 32.4 | 41.31 | 31.84 | 40.21 | 46.93 | 38.73 |
| EBITDA 1 | -21.15 | -6.663 | -1.28 | 3.837 | 8.408 | 5.209 |
| EBIT 1 | -26.56 | -11.74 | -3.84 | 2.811 | 8.108 | 4.784 |
| Net income 1 | -26.45 | -14.94 | -21.96 | 0.802 | 6.702 | 24.58 |
| Net Debt 1 | 2.11 | 10.65 | 11.26 | 7.694 | 4.395 | -1.322 |
| Reference price 2 | 3.140 | 7.470 | 1.040 | 1.080 | 2.698 | 1.230 |
| Nbr of stocks (in thousands) | 4,042 | 4,174 | 4,267 | 4,345 | 4,401 | 4,429 |
| Announcement Date | 01/04/21 | 31/03/22 | 27/03/23 | 01/04/24 | 31/03/25 | 30/03/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 45.15M | |
| -168.11x | 13.93x | -190.67x | -.--% | 40B | |
| 19.93x | 1.91x | 11.03x | 1.02% | 23.53B | |
| 17.02x | 1.33x | 7.56x | 5.11% | 7.28B | |
| 352.56x | - | - | - | 5.41B | |
| 46.67x | 8.3x | 29.51x | 1.11% | 2.89B | |
| -22.52x | - | - | - | 2B | |
| -34.01x | - | - | -.--% | 1.97B | |
| 31.71x | 1.13x | 9.45x | 0.8% | 1.82B | |
| 12.36x | 1.29x | 5.07x | 6.12% | 1.65B | |
| Average | 28.40x | 4.65x | -21.34x | 2.02% | 8.66B | |
| Weighted average by Cap. | -47.65x | 8.30x | -93.32x | 0.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IDXG Stock
- Valuation Interpace Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
